MEI Pharma Files 8-K with Corporate Updates
Ticker: LITS · Form: 8-K · Filed: Sep 10, 2025 · CIK: 1262104
| Field | Detail |
|---|---|
| Company | Mei Pharma, INC. (LITS) |
| Form Type | 8-K |
| Filed Date | Sep 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00000002 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-K, disclosure
Related Tickers: MEIP
TL;DR
MEI Pharma filed an 8-K on 9/10/25 for corporate updates and financial docs.
AI Summary
MEI Pharma, Inc. filed an 8-K on September 10, 2025, reporting amendments to its articles of incorporation or bylaws, a Regulation FD disclosure, and financial statements and exhibits. The filing details the company's principal executive offices located at 9920 Pacific Heights Blvd., Suite 150, San Diego, California, 92121.
Why It Matters
This 8-K filing indicates routine corporate actions and disclosures by MEI Pharma, Inc., providing transparency to investors regarding its governance and financial reporting.
Risk Assessment
Risk Level: low — The filing appears to be routine corporate housekeeping and disclosures, not indicating any immediate significant financial or operational risks.
Key Players & Entities
- MEI Pharma, Inc. (company) — Registrant
- September 10, 2025 (date) — Date of earliest event reported
- 9920 Pacific Heights Blvd., Suite 150, San Diego, California, 92121 (location) — Principal Executive Offices
FAQ
What specific amendments were made to MEI Pharma's articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary text.
What is the subject of the Regulation FD disclosure?
The provided text states that a Regulation FD Disclosure is part of the filing, but does not specify the content of the disclosure.
What financial statements and exhibits are included in this filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific documents are not detailed in the provided text.
When was MEI Pharma, Inc. incorporated and in which state?
MEI Pharma, Inc. was incorporated in Delaware.
What is the IRS Employer Identification Number for MEI Pharma, Inc.?
The IRS Employer Identification Number for MEI Pharma, Inc. is 51-0407811.
Filing Stats: 697 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2025-09-10 09:00:27
Key Financial Figures
- $0.00000002 — nge on which registered Common Stock, $0.00000002 par value MEIP The Nasdaq Stock Mar
Filing Documents
- meip-20250910.htm (8-K) — 51KB
- meip-ex3_1.htm (EX-3.1) — 12KB
- meip-ex99_1.htm (EX-99.1) — 17KB
- 0001262104-25-000009.txt ( ) — 194KB
- meip-20250910.xsd (EX-101.SCH) — 25KB
- meip-20250910_htm.xml (XML) — 5KB
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Effective September 10, 2025, MEI Pharma, Inc. (the "Company") changed its name to Lite Strategy, Inc. pursuant to an amendment to its amended and restated certificate of incorporation filed with the Secretary of State of the State of Delaware (the "Name Change"). Pursuant to the Delaware General Corporation Law, a stockholder vote was not necessary to effectuate the Name Change and it does not affect the rights of the Company's stockholders. On September 11, 2025, the Company's common stock, par value $0.00000002 per share, which trades on the NASDAQ Capital Market, will cease trading under the ticker symbol "MEIP" and commence trading under the ticker symbol "LITS." The foregoing description of the amendment to the Company's amended and restated certificate of incorporation does not purport to be complete and is qualified in its entirety by reference to the full text of the certificate of amendment, which is attached to this Current Report on Form 8-K as Exhibit 3.1 and is incorporated herein by reference.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 10, 2025, the Company issued a news release announcing the Name Change and new ticker symbol. The news release is being furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information in this item, including Exhibit 99.1, is being furnished to the Securities and Exchange Commission and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. This information shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Exhibit Title 3.1 Certificate of Amendment . 99.1 Press release, dated September 10, 2025 . 104 Cover Page Interactive Data File (formatted as inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MEI PHARMA, INC. Date: September 10, 2025 By: /s/ Justin J. File Justin J. File Acting Chief Executive Officer, Chief Financial Officer and Secretary